Tolgar Lütfi Kumral1, Okan Dikker2, Güven Yıldırım3, Semih Karaketir4, Cem Altındağ5, Mehmet Can Çakın6, Hüseyin Sarı4, Deniz Özcan7. 1. Department of Otorhinolaryngology-Head and Neck Surgery, Okmeydanı Training and Research Hospital, Darülaceze Cad. No: 25 Okmeydanı-Şişli, postal code: 34400, Istanbul, Turkey. tolgins@hotmail.com. 2. Department of Biochemistry, Okmeydanı Training and Research Hospital, Istanbul, Turkey. 3. Department of Otorhinolaryngology-Head and Neck Surgery, Giresun University Medical Faculty, Giresun, Turkey. 4. Department of Otorhinolaryngology-Head and Neck Surgery, Okmeydanı Training and Research Hospital, Darülaceze Cad. No: 25 Okmeydanı-Şişli, postal code: 34400, Istanbul, Turkey. 5. Department of Otorhinolaryngology-Head and Neck Surgery, Istinye Hospital, Istanbul, Turkey. 6. Department of Medical Biology, Cerrahpaşa University Medical Faculty, İstanbul, Turkey. 7. Department of Pathology, Okmeydanı Training and Research Hospital, İstanbul, Turkey.
Abstract
PURPOSE: To investigate the effect of thymic stromal lymphopoietin on the development of chronic otitis media with effusion MATERIALS AND METHODS: This study was conducted on 40 patients who had adenoidectomy operation. The objects were divided into two groups. Group 1; adenoidectomy with chronic serous otitis media, group 2; adenoidectomy without chronic serous otitis media. Serum and tissue thymic stromal lymphopoietin levels were measured by ELISA. Serum and tissue TLSP levels, mast cell count, adenoid size were compared between the groups. RESULTS: Twenty-four (60%) of patients were female and 16 (40%) were male. Twenty patients (55%) had adenoid hypertrophy with chronic serous otitis media, and 18 (45%) had adenoid hypertrophy without chronic serous otitis media. The mean age of the patients was 6.21 ± 2.31 years. The mean mast cell count was significantly higher in group 1 compared with group 2 (p = 0.017). The mean tissue thymic stromal lymphopoietin measurement was also significantly higher in group 1 than group 2 (p = 0.023). However, there was no significant difference in regards to serum levels between the groups (p = 0.480). CONCLUSION: The number of mast cells as well as thymic stromal lymphopoietin levels in the adenoids of children was significantly high in the chronic serous otitis media patients. The release of thymic stromal lymphopoietin from the adenoid tissue plays a role in initiating and maintaining a local inflammatory reaction in the eustachian tube that may lead eventually to middle ear effusion in non-atopic patients.
PURPOSE: To investigate the effect of thymic stromal lymphopoietin on the development of chronic otitis media with effusion MATERIALS AND METHODS: This study was conducted on 40 patients who had adenoidectomy operation. The objects were divided into two groups. Group 1; adenoidectomy with chronic serous otitis media, group 2; adenoidectomy without chronic serous otitis media. Serum and tissue thymic stromal lymphopoietin levels were measured by ELISA. Serum and tissue TLSP levels, mast cell count, adenoid size were compared between the groups. RESULTS: Twenty-four (60%) of patients were female and 16 (40%) were male. Twenty patients (55%) had adenoid hypertrophy with chronic serous otitis media, and 18 (45%) had adenoid hypertrophy without chronic serous otitis media. The mean age of the patients was 6.21 ± 2.31 years. The mean mast cell count was significantly higher in group 1 compared with group 2 (p = 0.017). The mean tissue thymic stromal lymphopoietin measurement was also significantly higher in group 1 than group 2 (p = 0.023). However, there was no significant difference in regards to serum levels between the groups (p = 0.480). CONCLUSION: The number of mast cells as well as thymic stromal lymphopoietin levels in the adenoids of children was significantly high in the chronic serous otitis media patients. The release of thymic stromal lymphopoietin from the adenoid tissue plays a role in initiating and maintaining a local inflammatory reaction in the eustachian tube that may lead eventually to middle ear effusion in non-atopic patients.